Publication
Gonzalez-Manzanares R, et al. Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI Trial. J Am Heart Assoc, 2026
PMID 42885795
Анализ post hoc рандомизированного испытания DapaTAVI (1222 пациента после TAVI): у хрупких пациентов дапаглифлозин был связан с меньшим риском смерти от любой причины или ухудшения сердечной недостаточности за год (ОР 0,53; 95% ДИ 0,36–0,77), у предхрупких и крепких — нет; P взаимодействия 0,021. Анализ подгрупп требует подтверждения.
Also in the catalogue
- Zhong J, et al. Initial Direct Oral Anticoagulants Versus Warfarin After Cerebral Venous Thrombosis: A Target Trial Emulation. Stroke, 2026Publication
- Wang X, et al. Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI). J Clin Oncol, 2026Publication
- Xue F, et al. Thyroid hormone receptor-β agonist simedeutirom (HSK31679) for Chinese patients with MASH: a 52-week phase 2b trial. Lancet Gastroenterol Hepatol, 2026Publication
- Sekiguchi M, et al. Serrated polyp detection rates beyond adenoma detection rate for postcolonoscopy colorectal cancer: findings from the SCREESCO trial. Endoscopy, 2026Publication
- Juesas Á, et al. Effects of aquatic and land-based resistance training on hip bone health in overweight older women: A 32-week randomized controlled trial. Arch Gerontol Geriatr, 2026Publication
- Li CM, et al. Hearing loss, hearing-aid use, and mortality risk: IPD meta-analysis (Australia, Iceland, USA) with replication in Norway. Lancet Healthy Longev, 2026Publication
Scales
Identifiers
- PMID
- 42885795
- DOI
- 10.1161/JAHA.126.051379
Original sources
Details
- Journal
- J Am Heart Assoc
- Year
- 2026
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.